Prof. Dr. med. / MD-PhD Cyrill A. Rentsch

Lampart, Franziska L., Vetter, Roman, Yamauchi, Kevin A., Wang, Yifan, Runser, Steve, Strohmeyer, Nico, Meer, Florian, Hussherr, Marie-Didiée, Camenisch, Gieri, Seifert, Hans-Helge, Rentsch, Cyrill A., Le Magnen, Clémentine, Müller, Daniel J., Bubendorf, Lukas, & Iber, Dagmar. (2025). Morphometry and mechanical instability at the onset of epithelial bladder cancer. Nature Physics. https://doi.org/10.1038/s41567-024-02735-2

Elyan, Anas, Saba, Karim, Sigle, August, Wetterauer, Christian, Engesser, Christian, Püschel, Heike, Attianese, Sara, Maurer, Patrick, Deckart, Alexander, Cathomas, Richard, Strebel, Räto T., Gratzke, Christian, Seifert, Helge H., Rentsch, Cyrill A., & Mortezavi, Ashkan. (2024). Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort. European Urology Focus, 10(4), 620–626. https://doi.org/10.1016/j.euf.2023.09.016

Engesser, Christian, Philipp, Brantner, Gahl, Brigitta, Matthias, Walter, Julian, Gehweiler, Seifert, Helge, Subotic, Svetozar, Rentsch, Cyrill, Wetterauer, Christian, Bubendorf, Lukas, Vlajnic, Tatjana, Hosseini, Albolfazl, & Ebbing, Jan. (2024). 3D-printed model for resection of positive surgical margins in robot-assisted prostatectomy [Journal-article]. BJU International. https://doi.org/10.1111/bju.16595

Flury-Sutter, Sarah, Heuzeroth, Frederick, Arbelaez, Emilio, Bubendorf, Lukas, Püschel, Heike, Hayoz, Stefanie, & Rentsch, Cyrill A. (2024). Efficacy and tolerability of bacillus Calmette-Guérin strain Russia for the treatment of non-muscle-invasive bladder cancer: Analysis of a prospective registry [Journal-article]. Canadian Urological Association Journal, 18(7). https://doi.org/10.5489/cuaj.8552

Heuzeroth, Frederick, Wetterauer, Christian, Boll, Daniel, Westhoff, Timm H., Dreher, Maeve, Seifert, Helge, Rentsch, Cyrill, & Ebbing, Jan. (2024). Exploratory testing of functional blood oxygenation level dependent-MRI to image the renoprotective effect of Remote Ischaemic PreConditioning during partial nephrectomy. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-83643-6

Neubauer, Moritz C., Nicolas, Guillaume P., Bauman, Andreas, Fani, Melpomeni, Nitzsche, Egbert, Afshar-Oromieh, Ali, Forrer, Flavio, Rentsch, Cyril, Stenner, Frank, Templeton, Arnoud, Schäfer, Niklaus, Wild, Damian, & Chirindel, Alin. (2024). Early response monitoring during [ 177 Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging, 51, 1185–1193. https://doi.org/10.1007/s00259-023-06536-2

Segeroth, Martin, Breit, Hanns-Christian, Wasserthal, Jakob, Bach, Michael, Rentsch, Cyrill, Matthias, Marc, Wetterauer, Christian, Merkle, Elmar Max, & Boll, Daniel Tobias. (2024). AI-Based Evaluation of Prostate MR Imaging at a Modern Low-field 0.55 T Scanner Compared to 3 T in a Screening Cohort. Academic Radiology. https://doi.org/10.1016/j.acra.2024.11.024

Vlajnic, Tatjana, Chijioke, Obinna, Roma, Luca, Savic Prince, Spasenija, Zellweger, Tobias, Rentsch, Cyrill A., & Bubendorf, Lukas. (2024). Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma. Modern Pathology, 37. https://doi.org/10.1016/j.modpat.2024.100495

Vlajnic, Tatjana, Müller, David C., Ruiz, Christian, Schönegg, René, Seifert, Hans-Helge, Thalmann, George N., Zellweger, Tobias, Le Magnen, Clémentine, Rentsch, Cyrill A., & Bubendorf, Lukas. (2024). Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer. Cancer Reports, 7. https://doi.org/10.1002/cnr2.1953

Wetterauer, Christian, Matthias, Mark, Pueschel, Heike, Deckart, Alexander, Bubendorf, Lukas, Mortezavi, Ashkan, Arbelaez, Emilio, Jean Winkel, David, Heye, Tobias, Boll, Daniel T., Merkle, Elmar, Hayoz, Stefanie, Seifert, Helge H., & Rentsch, Cyrill A. (2024). Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING). European Urology Focus, 10(2), 332–338. https://doi.org/10.1016/j.euf.2024.02.006

Würnschimmel, Christoph, Menges, Dominik, Kwiatkowski, Maciej, Sigg, Silvan, Prause, Lukas, Mattei, Agostino, Engeler, Daniel, Eberli, Daniel, Seifert, Helge, Valerio, Massimo, Rentsch, Cyrill A., & Mortezavi, Ashkan. (2024). Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology. Swiss Medical Weekly, 154. https://doi.org/10.57187/s.3626

Bratic Hench, Ivana, Roma, Luca, Conticelli, Floriana, Bubendorf, Lenard, Calgua, Byron, Le Magnen, Clémentine, Piscuoglio, Salvatore, Rubin, Mark A., Chirindel, Alin, Nicolas, Guillaume P., Vlajnic, Tatjana, Zellweger, Tobias, Templeton, Arnoud J., Stenner, Frank, Ruiz, Christian, Rentsch, Cyrill, & Bubendorf, Lukas. (2023). Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer [Journal-article]. Cancers, 16(1), 45. https://doi.org/10.3390/cancers16010045

Ruiz, Christian, Alborelli, Ilaria, Manzo, Massimilinao, Calgua, Byron, Keller, Eveline Barbara, Vuaroqueaux, Vincent, Quagliata, Luca, Rentsch, Cyrill A., Spagnoli, Giulio Cesare, Diener, Pierre André, Bubendorf, Lukas, Morant, Rudolf, & Eppenberger-Castori, Serenella. (2023). Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy. Pathobiology, 90(6), 400–408. https://doi.org/10.1159/000531175

Wetterauer, C., Matthias, M., Pueschel, H., Deckart, A., Bubendorf, L., Mortezavi, A., Arbelaez, E., Winkel, D. J., Heye, T., Boll, D. T., Merkle, E., Hayoz, S., Seifert, H. H., & Rentsch, C. A. (2023, September 8). Opportunistic PSA-free prostate cancer screening utilising biparametric MRI (VISIONING) [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2023.09.07.23295039

Leboutte, Francois, Engesser, Christian, Zahiti, Leutrim, Rentsch, Cyrill A., Seifert, Helge, Anding, Ralf, Hund-Georgiadis, Margret, Möhr, Sandra, & Walter, Matthias. (2023). Prevalence of Unfavorable Video-Urodynamic Findings and Clinical Implications in Patients with Minimally Conscious State/Unresponsive Wakefulness Syndrome: A Retrospective Descriptive Analysis. Biomedicines, 11(9). https://doi.org/10.3390/biomedicines11092432

Lampart, F. L., Vetter, R., Wang, Y., Yamauchi, K. A., Strohmeyer, N., Meer, F., Hussherr, M.-D., Camenisch, G., Seifert, H.-H., Rentsch, C. A., Magnen, C. L., Müller, D. J., Bubendorf, L., & Iber, D. (2023, August 18). Morphometry and mechanical instability at the onset of epithelial bladder cancer [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2023.08.17.553533

Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, & Cathomas R. (2023). Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): Intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - Protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). BMJ Open, 13(6), e067634. https://doi.org/10.1136/bmjopen-2022-067634

Garioni, Michele, Tschan, Viviane J., Blukacz, Lauriane, Nuciforo, Sandro, Parmentier, Romuald, Roma, Luca, Coto-Llerena, Mairene, Pueschel, Heike, Piscuoglio, Salvatore, Vlajnic, Tatjana, Stenner, Frank, Seifert, Hans-Helge, Rentsch, Cyrill A., Bubendorf, Lukas, & Le Magnen, Clémentine. (2023). Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. Npj Precision Oncology, 7. https://doi.org/10.1038/s41698-023-00466-w

Bacon JVW, Müller DC, Ritch E, Annala M, Dugas SG, Herberts C, Vandekerkhove G, Seifert H, Zellweger T, Black PC, Bubendorf L, Wyatt AW, & Rentsch CA. (2022). Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. European Urology Oncology, 5(6), 677–686. https://doi.org/10.1016/j.euo.2021.11.002

Rentsch CA, Hayoz S, & Cathomas RL. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study. European Urology, 81(5), 542. https://doi.org/10.1016/j.eururo.2022.01.021

Rentsch CA, Thalmann GN, Lucca I, Kwiatkowski M, Wirth GJ, Strebel RT, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Torpai R, Bubendorf L, Wicki A, Roth B, Bosshard P, Püschel H, Boll DT, Hefermehl L, Roghmann F, et al. (2022). A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. European Urology Oncology, 5(2), 195–202. https://doi.org/10.1016/j.euo.2021.12.006

Vlajnic T, Brunner P, Eppenberger-Castori S, Rentsch CA, Zellweger T, & Bubendorf L. (2022). High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. Pathobiology, 89(2), 74–80. https://doi.org/10.1159/000519007

Wetterauer C, Federer-Gsponer JR, Leboutte FDJP, Mona R, Ebbing J, Rentsch CA, Manka L, Seifert HH, Wyler S, Recker F, & Kwiatkowski M. (2022). Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies. Urologia Internationalis, 106(1), 83–89. https://doi.org/10.1159/000517300

Bausch K, Wetterauer C, Diethelm J., Ebbing J, Boll DT, Dill P, Rentsch C.A., & Seifert HH. (2021). Enhancing disease awareness for tuberous sclerosis complex in patients with radiologic diagnosis of renal angiomyolipoma: an observational study. BMC Nephrology, 22(1), 47. https://doi.org/10.1186/s12882-021-02253-w

Rentsch C.A., Hayoz S., & Cathomas R. (2021). Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer. The Lancet Oncology, 22(9), e379. https://doi.org/10.1016/s1470-2045(21)00390-9

Servant R, Garioni M, Vlajnic T, Blind M, Pueschel H, Müller DC, Zellweger T, Templeton AJ, Garofoli A, Maletti S, Piscuoglio S, Rubin MA, Seifert H, Rentsch CA, Bubendorf L, & Le Magnen C. (2021). Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. The Journal of Pathology, 254(5), 543–555. https://doi.org/10.1002/path.5698

Winkel DJ, Wetterauer C, Matthias MO, Lou B, Shi B, Kamen A, Comaniciu D, Seifert HH, Rentsch CA, & Boll DT. (2020). Autonomous detection and classification of pi-rads lesions in an mri screening population incorporating multicenter-labeled deep learning and biparametric imaging: Proof of concept. Diagnostics, 10(11). https://doi.org/10.3390/diagnostics10110951

Federer-Gsponer JR, Müller DC, Zellweger T, Eggimann M, Marston K, Ruiz C, Seifert HH, Rentsch CA, Bubendorf L, & Le Magnen C. (2020). Patterns of stemness-associated markers in the development of castration-resistant prostate cancer. The Prostate, 80(13), 1108–1117. https://doi.org/10.1002/pros.24039

Dell-Kuster S, Rentsch CA, Steiner LA, & Rosenthal R. (2020). The Importance of Standardised Recording of Intraoperative Adverse Events: Key Features of an Ideal Classification System (Patent No. 5). 77(5), Article 5. https://doi.org/10.1016/j.eururo.2020.01.024

Rentsch CA, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoiu M, Berardi S, et al. (2020). Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. OncoImmunology, 9(1), 1748981. https://doi.org/10.1080/2162402X.2020.1748981

Dugas SG, Müller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW, Wyatt AW, Rentsch CA, & Bubendorf L. (2019). Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathology, 127(9), 578–585. https://doi.org/10.1002/cncy.22167

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O’Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, et al. (2019). ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 37(1), 51–60. https://doi.org/10.1007/s00345-018-2438-9

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, et al. (2018). Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. The Prostate, 78(16), 1262–1282. https://doi.org/10.1002/pros.23701

Omlin, Aurelius, Spahn, Martin, Beyer, Jörg, Eberli, Daniel, Gillessen, Silke, Jochum, Wolfram, Kueng, Marc, Nitzsche, Egbert, Rentsch, Cyrill A, Roggero, Enrico, Schmid, Hans-Peter, Stenner, Frank, Templeton, Arnoud J, Templeton, Arnoud J, Wild, Damian, Wyler, Stephen, Zwahlen, Daniel, & Cathomas, Richard. (2018). [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. Praxis, 107(19), 1043–1051. https://doi.org/10.1024/1661-8157/a003054

Rentsch CA, Derré L, Dugas SG, Wetterauer C, Federer-Gsponer JR, Thalmann GN, & Ingersoll MA. (2018). Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy. European urology focus, 4(4), 485–493. https://doi.org/10.1016/j.euf.2018.10.010

Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, & Ruiz C. (2018). Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. The Journal of Pathology, 245(1), 74–84. https://doi.org/10.1002/path.5052

Müller DC, Rämö M, Naegele K, Ribi S, Wetterauer C, Perrina V, Quagliata L, Vlajnic T, Ruiz C, Balitzki B, Grobholz R, Gosert R, Ajuh ET, Hirsch HH, Bubendorf L, & Rentsch CA. (2018). Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus. The Journal of pathology, 244(3), 265–270. https://doi.org/10.1002/path.5012

Wetterauer, C, Rieken, M, Püschel, H, Ebbing, J, Papachristofilou, A, Gasser, T, & Rentsch, CA. (2018). Utility of cell based urinary tests in the follow-up after prostate cancer radiotherapy. Annals of Urologic Research, 1(2).

Rentsch CA, Müller DC, Ruiz C, & Bubendorf L. (2017). Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation? (Patent No. 6). 72(6), Article 6. https://doi.org/10.1016/j.eururo.2017.06.022

Stenner, Frank, Rothschild, Sacha I, Betticher, Daniel, Caspar, Clemens, Morant, Rudolf, Popescu, Razvan, Rauch, Daniel, Huber, Urs, Zenhäusern, Reinhard, Rentsch, Cyrill, & Cathomas, Richard. (2017). Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. Clinical genitourinary cancer. https://doi.org/10.1016/j.clgc.2017.08.003

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, & Derré L. (2017). ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. The Journal of clinical investigation, 127(8), 2916–2929. https://doi.org/10.1172/jci89717

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, et al. (2017). Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(14), 1530–1541. https://doi.org/10.1200/jco.2016.69.0677

Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, & Kaufmann SHE. (2017). The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Frontiers in immunology, 8, 1147. https://doi.org/10.3389/fimmu.2017.01147

Offermann A, Vlasic I, Syring I, Vogel W., Ruiz C, Zellweger T, Rentsch C.A., Hagedorn S., Behrends J, Nowak M., Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, & Perner S. (2017). MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget, 8(5), 7964–7976. https://doi.org/10.18632/oncotarget.13860

Rentsch C.A., Muller D.C., Ruiz C, & Bubendorf L. (2016). Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer. European Urology, 70(1), 83–84. https://doi.org/10.1016/j.eururo.2016.02.050

James, Nicholas D., Sydes, Matthew Robert, Clarke, Noel W., Mason, Malcolm David, Dearnaley, David P., Spears, Melissa Ruth, Ritchie, Alastair W. S., Russell, J. Martin, Parker, Chris C., Rentsch, Cyrill A., Wallace, Jan, Barber, Jim, Lydon, Anna, & Parmar, Mahesh K. B. (2016). Celecoxib with or without zoledronic acid for hormone-naive prostate cancer: Survival results from STAMPEDE (NCT00268476). 34. AMER SOC CLINICAL ONCOLOGY.

Ebbing J, Seibert F.S., Pagonas N, Bauer F., Miller K, Kempkensteffen C., Günzel K, Bachmann A., Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N., & Westhoff TH. (2016). Dynamics of urinary calprotectin after renal ischaemia. PLoS ONE, 11(1). https://doi.org/10.1371/journal.pone.0146395

Rentsch CA, Stenner F, Ruiz C, & Bubendorf L. (2015). Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep. (Patent No. 6). 68(6), Article 6. https://doi.org/10.1016/j.eururo.2015.07.050

Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A., Ruiz C, Dirnhofer S, Bubendorf L, & Rentsch C.A. (2015). Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice. Prostate, 75(6), 585–592. https://doi.org/10.1002/pros.22939

Vlajnic T, Oeggerli M, Rentsch C, Püschel H, Zellweger T, Thalmann GN, Ruiz C, & Bubendorf L. (2014). Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Archiv, 465(6), 637–642. https://doi.org/10.1007/s00428-014-1665-8

Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, & Rentsch CA. (2014). Incidental prostate cancer prevalence at radical cystoprostatectomy—importance of the histopathological work-up. Virchows Archiv, 465(6), 629–636. https://doi.org/10.1007/s00428-014-1656-9

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, & Thalmann GN. (2014). Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. European Urology, 66(4), 677–688. https://doi.org/10.1016/j.eururo.2014.02.061

Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, Thalmann GN, & Aebersold DM. (2014). Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiation oncology (London, England), 9, 122. https://doi.org/10.1186/1748-717x-9-122

Schmid S.C., Gschwend J.E., Retz M., & Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft e. V. (AUO). (2014). [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder]. Aktuelle Urologie, 45(1), 55–63; quiz 64–5. https://doi.org/10.1055/s-0033-1360281

Shaikhibrahim Z, Offermann A., Braun M, Menon R., Syring I, Nowak M., Halbach R., Vogel W., Ruiz C, Zellweger T, Rentsch C.A., Svensson M., Andren O, Bubendorf L, Biskup S, Duensing S., Kirfel J, & Perner S. (2014). MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocrine-Related Cancer, 21(4), 663–675. https://doi.org/10.1530/erc-14-0171

Subotic S, Weiss H, Wyler S, Rentsch CA, Rassweiler J, Bachmann A, & Teber D. (2013). Dismembered and non-dismembered retroperitoneoscopic pyeloplasty for the treatment of ureteropelvic junction obstruction in children. World journal of urology, 31(3), 689–695. https://doi.org/10.1007/s00345-012-0887-0

Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, & Ruiz C. (2013). Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer, 20(3), 403–413. https://doi.org/10.1530/erc-12-0402

Muller G., Bachmann A., & Rentsch C.A. (2013). Reply. Urology, 81(4), 843. https://doi.org/10.1016/j.urology.2012.10.071

Müller G, Bonkat G, Rieken M, Wyler SF, Bubendorf L, Püschel H, Gasser TC, Bachmann A, & Rentsch CA. (2013). Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols. Urology, 81(4), 837–842. https://doi.org/10.1016/j.urology.2012.10.068

Le Magnen, Clémentine, Bubendorf, Lukas, Rentsch, Cyrill A, Mengus, Chantal, Gsponer, Joel, Zellweger, Tobias, Rieken, Malte, Thalmann, George N, Cecchini, Marco G, Germann, Markus, Bachmann, Alexander, Wyler, Stephen, Heberer, Michael, & Spagnoli, Giulio C. (2013). Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clinical Cancer Research, 19(19), 5361–5371. https://doi.org/10.1158/1078-0432.ccr-12-2857

Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, & Breban R. (2013). BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. PloS one, 8(2), e56327. https://doi.org/10.1371/journal.pone.0056327

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, & Rentsch CA. (2012). High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth. The Prostate, 72(15), 1678–1687. https://doi.org/10.1002/pros.22521

Biot C, Rentsch C.A., Gsponer J.R., Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C., Bachmann A, Bousso P, Demangel C, Peduto L., Thalmann GN, & Albert ML. (2012). Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Science Translational Medicine, 4(137). https://doi.org/10.1126/scitranslmed.3003586

Breban R, Bisiaux A, Biot C, Rentsch C, Bousso P, & Albert ML. (2012). Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. Oncoimmunology, 1(1), 9–17. https://doi.org/10.4161/onci.1.1.17884

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, & Barrett MT. (2012). Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PloS one, 7(11), e50586. https://doi.org/10.1371/journal.pone.0050586

Ghadjar P, Rentsch CA, Isaak B, Behrensmeier F, Thalmann GN, & Aebersold DM. (2011). Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy, 10(4), 286–294. https://doi.org/10.1016/j.brachy.2010.09.005

Bonkat, Gernot, Rieken, Malte, Rentsch, Cyrill A, Wyler, Stephen, Feike, Antje, Schäfer, Juliane, Gasser, Thomas, Trampuz, Andrej, Bachmann, Alexander, & Widmer, Andreas F. (2011). Improved detection of microbial ureteral stent colonisation by sonication. World Journal of Urology, 29(1), 133–138. https://doi.org/10.1007/s00345-010-0535-5

Cathomas R., Helbling D., Stenner F., Rothermundt C., Rentsch C., Shahin O., Seifert H.-H., Zaugg K., Lorch A., Mayer F., Beyer J., De Santis M., & Gillessen S. (2010). Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: A joint effort. Swiss Medical Weekly, 140(25-26), 356–369.

Cathomas,Richard, Helbling,Daniel, Stenner,Frank, Rothermundt,Christian, Rentsch,Cyrill, Shahin,Osama, Seifert,Hans-Helge, Zaugg,Kathrin, Lorch,Anja, Mayer,Frank, Beyer,Jörg, De Santis,Maria, & Gillessen,Silke. (2010). Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: A joint effort. Swiss Medical Weekly, 140(25-26), 356–369. https://doi.org/10.4414/smw.2010.12993

Gluderer S, Brunner E, Germann M, Jovaisaite V, Li C, Rentsch CA, Hafen E, & Stocker H. (2010). Madm (Mlf1 adapter molecule) cooperates with Bunched A to promote growth in Drosophila. Journal of biology, 9(1), 9. https://doi.org/10.1186/jbiol216

Karamitopoulou E, Rentsch CA, Markwalder R, Vallan C, Thalmann GN, & Brunner T. (2010). Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology, 42(1), 37–42. https://doi.org/10.3109/00313020903434397

Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, & Cecchini MG. (2009). In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. The Prostate, 69(15), 1683–1693. https://doi.org/10.1002/pros.21018

Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, & Aebersold DM. (2009). Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 91(2), 237–242. https://doi.org/10.1016/j.radonc.2008.12.007

Rentsch CA, Cecchini MG, & Thalmann GN. (2009). Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. Swiss Medical Weekly, 139(15-16), 220–225. https://doi.org/10.4414/smw.2009.12284

Ghadjar P, Keller T, Rentsch CA, Isaak B, Behrensmeier F, Stroux A, Thalmann GN, & Aebersold DM. (2009). Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy, 8(1), 45–51. https://doi.org/10.1016/j.brachy.2008.09.004

Rentsch, Cyrill A, & Bachmann, Alexander. (2009). Editorial comment on: Expression of aquaporin 1 in primary renal tumors : a prognostic indicator of clear-cell renal cell carcinoma. European Urology, 56(4), 699. https://doi.org/10.1016/j.eururo.2008.10.015

Vetsch G, Baumann CK, Kläy M, Leupin N, Rentsch C, Mueller-Garamvölgyi E, Bürgi U, & Schiemann U. (2008). [Malignant lymphoma of the prostate--diagnosis on the second biopsy]. Medizinische Klinik (Munich, Germany : 1983), 103(4), 245–248. https://doi.org/10.1007/s00063-008-1034-y

Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, & van der Pluijm G. (2007). Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Research, 67(18), 8742–8751. https://doi.org/10.1158/0008-5472.CAN-06-2490

Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, & van der Pluijm G. (2007). BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. The American journal of pathology, 171(3), 1047–1057. https://doi.org/10.2353/ajpath.2007.070168

Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G, Löwik CW, Ackermann K, Pyerin W, Hamdy FC, Thalmann GN, & Cecchini MG. (2007). Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. The American journal of pathology, 170(1), 160–175. https://doi.org/10.2353/ajpath.2007.051276

Rentsch CA, Cecchini MG, Schwaninger R, Germann M, Markwalder R, Heller M, van der Pluijm G, Thalmann GN, & Wetterwald A. (2006). Differential expression of TGFβ-stimulated clone 22 in normal prostate and prostate cancer. International Journal of Cancer, 118(4), 899–906. https://doi.org/10.1002/ijc.21449

Rentsch CA, Aebersold DM, Merz V, & Studer UE. (2005). [Cancer of the prostate: importance of androgen deprivation and radiotherapy]. Revue medicale suisse, 1(19), 1303–1306.

Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, & Studer UE. (2003). A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. The Journal of urology, 169(1), 96–100; discussion 100. https://doi.org/10.1016/s0022-5347(05)64044-x

Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, & Studer UE. (2000). Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. The Journal of urology, 164(6), 2129–2133.